BWAY
BrainsWay Ltd.
BWAY has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
BWAY Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Stable | |
| Healthy |
BWAY's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
BWAY PE Valuation
BWAY has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
BWAY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
BWAY has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
BWAY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.37 | +147% |
| Q1 2026 | $0.28 | +133% |
| Q4 2025 | $0.18 | +80% |
| Q3 2025 | $0.15 | +114% |
| Q2 2025 | $0.15 | +650% |
| Q1 2025 | $0.12 | +$0.17 |
| Q4 2024 | $0.10 | +$0.22 |
| Q3 2024 | $0.07 | +$0.32 |
BWAY's earnings per share have climbed steadily: $0.37 over the past year, up 147% from the year before, and higher year over year for 12 quarters in a row.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
BWAY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $17.4M | +38% |
| Q1 2026 | $15.5M | +35% |
| Q4 2025 | $14.5M | +27% |
| Q3 2025 | $13.5M | +29% |
| Q2 2025 | $12.6M | +26% |
| Q1 2025 | $11.5M | +27% |
| Q4 2024 | $11.4M | +26% |
| Q3 2024 | $10.5M | +26% |
BWAY has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 14% | +9.4 points |
| Q1 2026 | 13% | +7.9 points |
| Q4 2025 | 13% | +9.4 points |
| Q3 2025 | 9.3% | +6.6 points |
| Q2 2025 | 4.6% | -1.3 points |
| Q1 2025 | 5% | +4 points |
| Q4 2024 | 3.8% | -108 points |
| Q3 2024 | 2.7% | +4.3 points |
BWAY's operating margin was 14% last quarter, up 9.4 points from the same quarter a year ago, near the top of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over BWAY on profitability, with a higher operating margin.
BWAY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $5.5M | -51% |
| Q1 2026 | $402K | -90% |
| Q4 2025 | -$759K | -130% |
| Q3 2025 | $586K | -40% |
| Q2 2025 | $11.2M | +2139% |
| Q1 2025 | $4M | +62% |
| Q4 2024 | $2.6M | +27% |
| Q3 2024 | $978K | +16% |
BWAY still generates free cash flow, though less than at its 2025 peak: $6M over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over BWAY on cash flow, with more consistent year-over-year improvement.
BWAY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.1% | +981K shares |
| 1 year | -47% | -17.7M shares |
| 3 years | -40% | -13.1M shares |
| 5 years | -39% | -12.8M shares |
| Available history | -8.5% | -1.9M shares |
BWAY has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
BWAY hasn't bought back shares in the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
BWAY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -4.5x | Net Cash |
| Q1 2026 | -4.1x | Net Cash |
| Q4 2025 | -5.2x | Net Cash |
| Q3 2025 | -6.6x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -10.0x | Net Cash |
| Q4 2024 | -11.9x | Net Cash |
| Q3 2024 | -8.6x | Net Cash |
BWAY has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
BWAY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.9 | Oversold |
| Stochastic | 5.3 | Oversold |
BWAY's weekly RSI is 30 (oversold) and its Stochastic is 5 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
BWAY PE vs Healthcare Sector
| Metric | BWAY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BWAY has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BWAY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.6 | 12% below |
| 20 week MA | $13.6 | 25% below |
| 50 week MA | $13.2 | 22% below |
| 100 week MA | $9.61 | 6.7% above |
| 200 week MA | $6.08 | 69% above |
BWAY has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
BWAY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.85 | $3.09 | -36% |
| 2021 | $3.09 | $3.76 | +22% |
| 2022 | $3.76 | $1.08 | -71% |
| 2023 | $1.08 | $3.24 | +200% |
| 2024 | $3.24 | $4.57 | +41% |
| 2025 | $4.57 | $9.69 | +112% |
| 2026 YTD | $9.69 | $10.3 | +5.8% |
BWAY has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.